Substance Use Disorders (SUD)Medicinal Chemistry & Drug DevelopmentMescaline

Dark Classics in Chemical Neuroscience: Mescaline

This review (2018) looks at the history, pharmacology, metabolism, and psychological effects of mescaline.

Authors

  • Cassels, B. K.
  • Sáez-Briones, P.

Published

ACS Chemical Neuroscience
meta Study

Abstract

Archeological studies in the United States, Mexico, and Peru suggest that mescaline, as a cactus constituent, has been used for more than 6000 years. Although it is a widespread cactus alkaloid, it is present in high concentrations in few species, notably the North American peyote (Lophophora williamsii) and the South American wachuma (Trichocereus pachanoi, T. peruvianus, and T. bridgesii). Spanish 16th century chroniclers considered these cacti “diabolic”, leading to their prohibition, but their use persisted to our days and has been spreading for the last 150 years. In the late 1800s, peyote attracted scientific attention; mescaline was isolated, and its role in the psychedelic effects of peyote tops or “mescal buttons” was demonstrated. Its structure was established by synthesis in 1929, and alternative routes were developed, providing larger amounts for pharmacological and biosynthetic research. Although its effects are attributed mainly to its action as a 5-HT2A serotonin receptor agonist, mescaline binds in a similar concentration range to 5-HT1A and α2A receptors. It is largely excreted unchanged in human urine, and its metabolic products are apparently unrelated to its psychedelic properties. Its low potency is probably responsible for its relative neglect by recreational substance users, as the successful search for structure-activity relationships in the hallucinogen field focused largely on finding more potent analogues. Renewed interest in the possible therapeutic applications of psychedelic drugs may hopefully lead to novel insights regarding the commonalities and differences between the actions of individual classic hallucinogens.

Available with Blossom Pro

Research Summary of 'Dark Classics in Chemical Neuroscience: Mescaline'

Introduction

Mescaline is one of the classic serotonergic psychedelics with an exceptionally long record of human use. Archaeological and ethnohistorical evidence indicates ingestion of mescaline-containing cacti for millennia: dried peyote tops (Lophophora williamsii) were radiocarbon-dated to about 5,800–6,000 years before present, a Trichocereus peruvianus spine cluster associated with artefacts dated to 6,200–6,800 YBP, and depictions of San Pedro (T. pachanoi) appear from at least 2,500 YBP. Despite this deep cultural history, contemporary use of isolated mescaline appears limited, probably because full psychedelic effects require relatively large oral doses (around 300 mg of the free base), whereas ingestion of peyote buttons or San Pedro brews remains common in some ceremonial and recreational contexts and has spread geographically over the last 150 years. This review sets out to synthesise knowledge on mescaline’s occurrence, chemistry, synthesis, biosynthesis, pharmacology, metabolism and structure–activity relationships (SAR). The authors survey historical reports, botanical and chemical analyses, early and mid-20th century human and animal pharmacology, and the development of mescaline analogues, identifying gaps in recent research and areas where renewed study might be productive for both basic neuroscience and potential therapeutic applications.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (17)

Papers cited by this study that are also in Blossom

Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)

Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)

Increased thalamic resting state connectivity as a core driver of LSD-induced hallucinations

Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)

Animal models of serotonergic psychedelics

Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)

Show all 17 references
Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions

González, D., Torrens, M., Farré, M. · BioMed Research International (2015)

56 cited
Acute pharmacological effects of 2C-B in humans: An observational study

Souza, D. C. D., Pérez, C., Papaseit, E. et al. · Frontiers in Pharmacology (2018)

79 cited
A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

296 cited
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited

Cited By (7)

Papers in Blossom that reference this study

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants

Mueller, L., Klaiber, A., Ley, L. et al. · Clinical Pharmacokinetics (2025)

Safety pharmacology of acute mescaline administration in healthy participants

Klaiber, A., Humbert‐Droz, M., Ley, L. et al. · British Journal of Clinical Pharmacology (2024)

4 cited
Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects

Klaiber, A., Schmid, Y., Becker, A. M. et al. · Translational Psychiatry (2024)

13 cited
Altered States of Consciousness During Ceremonial San Pedro Use

Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)

Mescaline: The forgotten psychedelic

Narine, K., Campbell, I., Dyck, J. et al. · Neuropharmacology (2022)

98 cited
5-HT2CR Is as Important as 5-HT2AR in Inducing Hallucinogenic Effects in Serotonergic Compounds

James Perez Custodio, R., Ortiz, D. M., Lee, H. J. et al. · SSRN (2022)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.